Typically, cost effectiveness analyses assume a constant price between drug approvals and loss of exclusivity. It is not clear, however, to what extent that assumption is valid, particularly after taking into account drug price discounts and rebates. A paper by Lin et al. (2024) uses 2007-2023 data on drug prices from SSR Health to answer…
Novartis’s Fabhalta is the first FDA-approved therapy for C3 glomerulopathy. But Apellis Pharmaceuticals’ Empaveli has superior clinical data, and that drug has been submitted for FDA review in the same rare kidney disease as well as another one that does not yet have an approved therapy. The post Novartis Nabs First FDA Nod in Rare…
That is the title of my paper out today in the Journal of Comparative Effectiveness Research written with co-authors Adam Kittai, Dipen Patel, Nadine Zawadzki, Vikram Shetty, Yazan Barqawi, and Joanna Rhodes. The abstract is below. Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and…
This chart collection compares health care spending in the U.S. and other industrialized countries, including data on health spending per person and the growth rate in recent years and over time.
SACRAMENTO, Calif. — A judge has initiated a federal court takeover of California’s troubled prison mental health system by naming the former head of the Federal Bureau of Prisons to serve as receiver, giving her four months to craft a plan to provide adequate care for tens of thousands of prisoners with serious mental illness….
Health insurance is often complicated, but understanding the basics helps you make better decisions about your coverage and care. This 10-question quiz touches on some terms you may encounter.
A bipartisan Senate bill would boost transparency and oversight of pharmacy benefit managers by changing how they’re paid, expanding reporting requirements and strengthening protections for pharmacies and taxpayers. The post Senators Introduce Bipartisan Bill to Increase Oversight of PBMs appeared first on MedCity News.
Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the class of targeted cancer therapies called antibody drug conjugates. The post Pfizer’s $10.5B Deal With One…
CMS’s recent announcement outlines federal requirements for healthcare provider taxes in Medicaid
By LEONARD D’ AVOLIO The murder of UnitedHealthcare CEO Brian Thompson has drawn attention to Americans’ frustration with the for profit healthcare insurance industry. Change is possible but less likely if people don’t understand how we got here, the real issues, and how they might be fixed. Health insurance wasn’t always run by big for…